Produced by AVE, it is a new serial of product with machine vision technology, low power screening, positioning, and high-power tracking recognition.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Medtronic has received a CE mark for its continuous glucose monitoring (CGM) device, Simplera, allowing the device to be marketed in the European Union.

Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

As the demand for the mass spectrometry market in China has rapidly increased, major domestic and international mass spectrometer manufacturers have accelerated their product registration efforts. In recent years, a variety of different types of mass spectrometry instruments have obtained NMPA certificates.

A systematic review of earlier studies has found that artificial intelligence (AI) and machine learning (ML) can support the diagnosis of polycystic ovarian syndrome (PCOS).

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted therapies.

Abbott (NYSE: ABT) and WW International, Inc. (NASDAQ: WW), known as WeightWatchers, announced today the availability of a connected app to help people living with diabetes understand how food and activity impact their glucose levels.

On August 24, NHC issued the Birth Defects Prevention and Control Plan (2023-2027), proposing that by 2027, China's birth defects prevention and control services will be more universally accessible, and that the prenatal genetic screening rate to reach 90%.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel. The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.

Danaher on Tuesday announced that it will provide Cepheid's tuberculosis test to the Global Fund to Fight AIDS, TB, and Malaria, as well as to less-developed countries eligible for Cepheid's Global Access Program, at cost.